PhaseBio Pharmaceuticals, Inc. (NasdaqGM:PHAS) said that it has filed for chapter 11 bankruptcy with plans to sell the assets of its lead program. The Malvern, Pa., clinical-stage biopharmaceutical company said it plans to seek bankruptcy court approval for an auction and sale process for its bentracimab program, which would be purchased free and clear of liens and interests.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | 0.00% | 0.00% | 0.00% |
1st Jan change | Capi. | |
---|---|---|
0.00% | 49 | |
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |
- Stock Market
- Equities
- PHAS.Q Stock
- News PhaseBio Pharmaceuticals, Inc.
- PhaseBio Files for Bankruptcy With Plans to Sell Assets